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Differential Distribution of microRNAs in Breast Cancer Grouped by Clinicopathological Subtypes
Jian-Yi Li, Shi Jia, Wen-Hai Zhang*, Yang Zhang, Ye Kang, Pi-Song Li heterogeneous microvessel distribution with significant hypoxia occurring in regions of decreased blood flow (Balsat et al., 2011) . The distribution of miRNAs in breast tumors might be an important factor in breast cancer angiogenesis, invasion and metastasis, and as such, is worth examining in some detail. In this study, we classified tumors according to their clinicopathological subtypes based on the St. Gallen Breast Cancer Treatment Consensus 2011 (Goldhirsch et al., 2011) . MiRNA Arrays were performed in the centers and edges of tumors from each clinicopathological subtype. Our data showed that many types of miRNAs were differentially distributed in the breast tumors. These results might further our understanding of the heterogeneity of miRNA expression in breast cancer.
Materials and Methods
Patients and groups
Thirty human breast tumor samples were obtained by open surgical resection from patients, who were treated at Shengjing Hospital of China Medical University (SJHCMU) between 2005 and 2012. Inclusion criteria were: invasive ductal carcinoma (IDC), tumor diameter between 2 and 3 cm, clinical stage II, no history of neoadjuvant therapy and radiotherapy, no family history of breast cancer and other cancers, and no accessory breast cancer. Pathological tumor stage was assessed according to the criteria described in the 6th edition of the American Joint Committee on Cancer (AJCC) staging manual. The tumors were classified into histological grades I-III according to the Nottingham combined histological grading system. Of those patients, six met the requirements and entered the Luminal A group; the patient characteristics in this group were: no lymph node metastases, histological grade I, human epidermal growth factor receptor 2 (Her2)-negative, vascular cancer embolus-negative, estrogen and progesterone receptorpositive, p53-negative, and Ki67 index less than 14%. Six patients met the requirements and entered the Luminal B Ki67+ group; the patient characteristics in this group were: no lymph node metastases, histological grade I, Her2-negative, vascular cancer embolus-negative, estrogen and progesterone receptor-positive, p53-negative, and Ki67 greater more than or equal to 14%. Six patients met the requirements and entered the Luminal B Her2+ group; the patient characteristics in this group were: lymph node metastases, Her2-positive, vascular cancer emboluspositive, and estrogen receptor-positive. Six met the requirements and entered the Her2 overexpression group; the patient characteristics in this group were: lymph node metastases, histological grade III, Her2-positive, vascular cancer embolus-positive, estrogen and progesterone receptor-negative, p53-positive, and Ki67 greater more than or equal to 14%. Six met the requirements and entered the triple-negative breast cancer (TNBC) group; the patient characteristics in this group were: lymph node metastases, histological grade III, Her2-negative, vascular cancer embolus-positive, estrogen and progesterone receptor-negative, p53-positive, Ki67 greater more than or equal to 14%, and epidermal growth factor receptor (EGFR) or cytokeratin 5/6 (CK5/6)-positive (Table  1) . Fluorescence in situ hybridization (FISH) analysis was performed on insulin-like growth factor 1 receptor (IGF1R) and EGFR protein overexpression (IHC+) tumors using the PathVysion HER2 DNA Probe Kit (Vysis; Downers Grove, IL, USA). Her2-positive staining was defined as FISH-positive, and Her2-negative staining was defined as IHC 0 or FISH-negative. We randomly chose 6 patients with benign tumors and normal breast tissues for the control group. All patients gave informed consent and signed the Informed Consent Sheet. This study was approved by the Ethics Committee of Shengjing Hospital.
Tumor samples
The largest section of the tumor, which was parallel DOI:http://dx.doi.org/10.7314/APJCP.2013.14.5.3197 Distribution of microRNAs in Different Sites of Various Breast Cancer Subtypes to the chest wall and more than 3 mm thick, was obtained by open surgery. The center and edge of the tumor were determined by eye, and the weight of each specimen was more than 30 mg ( Figure 1A ). Similar quantities of normal breast tissue were obtained from patients in the control group. All samples were stored at -80°C after quick freezing in liquid nitrogen.
MiRNA array
Since the entry criterion was stringent, it took a long time to collect each group of tumors. Therefore, we first collected samples for miRNA array from the Luminal A and Her2 overexpression groups. For each group of 6 samples, the center and edge fragments of the tumor were mixed with a similar sample from the control group; five such mixed samples (the central part of Luminal A -LA, the edge part of Luminal A -LB, the central part of Her2 overexpression -HA, the edge part of Her2 overexpression -HB, and Normal) were screened using miRNA arrays. The 6th generation miRCURYTM LNA Array (v.16.0) (Exiqon; Vedbaek, Denmari) contains more than 1891 capture probes, covering all human, mouse, and rat miRNAs annotated in miRBase 16.0, as well as all viral miRNAs related to these species. In addition, this array contains capture probes for 66 new miRPlus™ human miRNAs. Total RNA was isolated using TRIzol (Invitrogen; Carlsbad, CA, USA); the miRNeasy Mini Kit (QIAGEN; Spoorstraat, Netherlands) was used to obtain all RNA species, including miRNAs, according to the manufacturer's instructions,. RNA quality and quantity were measured using a nanodrop spectrophotometer (ND-1000, Nanodrop Technologies; Wilmington, DE, USA), and RNA integrity was determined by gel electrophoresis. After RNA isolation from the samples, the miRCURY™ Hy3™/Hy5™ Power labeling kit (Exiqon) was used according to the manufacturer's guidelines for miRNA labeling. One microgram of each sample was 3'-endlabeled with a Hy3TM fluorescent label, using T4 RNA ligase according to the procedure described below. Briefly, RNA in 2.0 μl of water was combined with 1.0 μl CIP buffer and CIP (Exiqon). The mixture was incubated for 30 min at 37°C, and was terminated by incubation for 5 min at 95°C. Then, 3.0 μl of labeling buffer, 1.5 μl of fluorescent label (Hy3TM), 2.0 μl of DMSO, and 2.0 μl of labeling enzyme were added to the mixture. The labeling reaction was incubated for 1 h at 16°C, and terminated by incubation for 15 min at 65°C. The Hy3TM-labeled samples were hybridized on the miRCURYTM LNA Array (v. 16.0) (Exiqon), according to the instructions in the array manual. The 25-μl mixture of Hy3TM-labeled samples and 25 μl hybridization buffer were denatured for 2 min at 95 °C, incubated on ice for 2 min, and then hybridized to the microarray for 16-20 h at 56°C in the 12-Bay Hybridization System (Hybridization SystemNimblegen Systems, Inc.; Madison, WI, USA), which provides active mixing action and constant incubation temperature to improve hybridization uniformity and enhance signals. Following hybridization, the slides were washed several times with wash buffer from the Exiqon kit, and finally, dried by centrifugation for 5 min at 400 rpm. The slides were then scanned using Axon GenePix 4000B microarray scanner (Axon Instruments; Foster City, CA, USA).
Next, samples from Luminal B Ki67+, Luminal B Her2+, and TNBC groups were collected for microarray. For each group of 6 samples, the center and edge fragments of the tumor were mixed with a similar sample from the control group; seven such mixed samples (the central part of Luminal B Ki67+ -LBKC, the edge part of Luminal B Ki67+ -LBKE, the central part of Luminal B Her2+ -LBHC, the edge part of Luminal B Her2+ -LBHE, the central part of TNBC -TNBCC, the edge part of TNBC -TNBCE, and Normal) were screened using miRNA arrays. Here, we performed the microarrays with the 7th generation of miRCURYTM LNA Array (v.18.0) (Exiqon), which contains 3100 capture probes, covering all human, mouse, and rat miRNAs annotated in miRBase 18.0, as well as all viral miRNAs related to these species. The experimental process was basically the same as the aforementioned protocol. These two screening procedures used the same control group.
Statistical analysis
Scanned images were imported into GenePix Pro 6.0 software (Axon) for grid alignment and data extraction. Replicated miRNAs were averaged, and miRNAs with intensities>=50 in all samples were chosen for calculating the normalization factor. Expressed data were normalized using the median normalization. After normalization, differentially expressed miRNAs were identified through Fold Change filtering. Hierarchical clustering was performed using MEV software (v 4.6, TIGR). 
Results
Preliminary identification of differentially expressed miRNAs in breast cancer
We obtained 6 kinds of patterns in the differentially expressed miRNAs for each clinicopathological subtype which included: center/normal≥2; center/normal≤0.5; center/edge≥2; center/edge≤0.5; edge/normal≥2; edge/ normal≤0.5 ( Figure 1B ). Four series of comparative analyses were performed in the 6 kinds of data which included: center/normal≥2 vs center/edge≥2 vs edge/ normal≥2; center/normal≥2 vs center/edge≤0.5 vs edge/ normal≥2; center/normal≤0.5 vs center/edge≥2 vs edge/ normal≤0.5; center/normal≤0.5 vs center/edge≤0.5 vs edge/normal≤0.5. We obtained 4 sequences of miRNA expression for each clinicopathological subtype: center>edge>normal; edge>center>normal; edge<center<normal; center<edge<normal (Figure 2 ). There were no miRNAs in accordance with LA>LB>Normal, LB>LA>Normal, LB<LA<Normal, HA>HB>Normal, HB>HA>Normal, and HA<HB<Normal. Fourteen series of miRNAs are shown in Table 2 , which includes 8 kinds of miRNAs for Luminal A subtype, 84 kinds for Luminal hsa-miR-4326 kshv-miR-K12-7-5p hsa-let-7f-5p; hsa-miR-93-5p hsa-miR-126-5p -84
hsa-miR-593-5p hsa-miR-325 hsa-miR-19a-3p; hsa-miR-32-5p hsa-miR-30c-2-3p ebv-miR-BART11-3p
hsa-miR-2114-3p hsa-miR-143-3p; hsa-miR-16-5p hsa-miR-4289 hsa-miR-676-3p hsa-miR-3653; hsa-miR-146a-5p hsa-miR-127-3p hsa-miR-381-5p hsa-miR-15a-5p; hsa-let-7b-5p hsa-miR-135a-5p hsa-miR-506-3p hsa-miR-15b-5p; hsa-miR-126-3p hsa-miR-3621 hsa-miR-4320 hsa-miR-29c-3p; hsa-miR-26b-5p hsa-miR-30c-1-3p hsa-miR-504 hsa-miR-30a-5p; hsa-miR-19b-3p hsa-miR-99a-3p hsa-miR-346 hsa-miR-148a-3p; hsa-miR-30e-5p hsv2-miR-H6-5p sv40-miR-S1-3p hsa-let-7a-5p; hsa-miR-30b-5p hsa-miR-3180/ hsa-miR-3180-3p hsa-miR-767-3p hsa-miR-106b-5p;hsa-miR-3607-3p hsa-miR-1288 hsa-miR-29b-3p; hsa-miR-142-5p hsa-miR-204-5p
hsa-miR-100-5p; hsa-miR-140-3p hsa-miR-648 hsa-miR-96-5p; hsa-miR-181a-5p hsa-miR-18b-3p
hsa-miR-148b-3p; hsa-miR-195-5p hsa-miR-520a-3p
hsa-miR-23a-3p; hsa-miR-424-5p hsa-miR-616-5p
hsa-miR-335-5p; hsa-miR-618 hsa-miR-199a-3p/hsa-miR-199b-3p hsa-miR-615-5p
hsa-miR-24-3p; hsa-miR-30a-3p hsa-miR-4269 hsa-miR-374a-5p; hsa-miR-665 hsa-miR-1225-3p hsa-miR-26a-5p; hsa-miR-30c-5p hsa-miR-1909-5p hsa-miR-342-3p; hsa-miR-497-5p hsa-miR-431-5p hsa-let-7i-5p; hsa-miR-98-5p hcmv-miR-US33-5p hsa-miR-374b-5p; hsa-miR-542-3p hsa-miR-1267 Luminal B Her2+ hsa-miR-148b-5p hsa-miR-2113 hsa-miR-135a-5p; hsa-miR-1915-3p -52 hsa-miR-3681-5p hsa-miR-1207-3p hcmv-miR-US33-3p hsa-miR-451a hsa-miR-1298 hsa-miR-3614-3p hsa-miR-3180/hsa-miR-3180-3p hsa-miR-492 hsa-miR-190b mcv-miR-M1-3p hsa-miR-3609; hsa-miR-497-5p hsa-miR-185-5p hsa-miR-297 hsa-miR-34c-3p hsa-miR-483-5p; hsa-miR-26b-5p hsa-miR-374b-5p hsa-miR-155-5p hsa-miR-219-1-3p hsa-miR-136-5p; hsa-miR-32-5p hsa-miR-4306 hsa-miR-183-5p hsa-miR-140-5p; hsa-miR-130a-3p hsa-miR-1224-3p hsa-miR-3183 hsa-miR-10b-5p; hsa-miR-30a-5p hsa-miR-10a-5p hsa-miR-105-3p hsa-miR-30c-1-3p hsa-miR-30e-5p hsa-miR-149-5p hsa-miR-335-5p; hsa-miR-126-3p hsa-miR-197-3p hsa-miR-100-5p; hsa-miR-377-3p hsa-miR-3653 hsa-miR-337-5p; hsa-miR-376c-3p hsa-miR-151a-5p hsa-miR-125b-5p hsa-miR-30b-5p hsa-miR-143-3p hsa-miR-205-5p Her2 OE hsa-miR-20a; hsa-miR-335 -13 hsa-miR-30b; hsa-miR-374a hsa-miR-126*; hsa-miR-30e hsa-miR-27a; hsa-miR-374c hsa-miR-20b; hsa-miR-10b hsa-miR-143; hsa-miR-126 hsa-miR-3607-3p TNBC hsa-miR-942 hsa-miR-3180-5p hsa-miR-142-3p; hsa-miR-199a-5p hsa-miR-30c-1-3p (Basal Like) hsa-miR-412 hsa-miR-3614-3p hsa-miR-15a-5p; hsa-miR-20a-5p hsa-miR-1469 -50
hsa-miR-122-3p hsa-miR-518e-3p hsa-miR-664a-5p hsa-miR-204-3p hsa-miR-4297 hsa-miR-521 hsa-miR-3607-5p hsa-miR-744-5p hsa-miR-632 hsa-miR-3913-5p hsa-miR-126-3p; hsa-miR-93-5p hsa-miR-711 hsa-miR-1225-5p hsa-let-7a-5p; hsa-miR-29c-3p hsa-miR-542-3p hsa-miR-190b hsa-miR-21-5p; hsa-miR-148a-3p hsa-miR-451a hsa-miR-33a-5p; hsa-miR-9-5p hsa-miR-483-5p hsa-miR- 142-5p; hsa-miR-195-5p hsa-miR-1908 hsa-miR-152; hsa-miR-140-3p hsa-miR-24-3p hsa-let-7g-5p; hsa-miR-196a-5p hsa-miR-30e-5p hsa-miR-145-5p; hsa-miR-26a-5p hsa-miR-374c-5p hsa-miR-22-3p; hsa-miR-374a-5p hsa-miR-3196 hsa-miR-144-3p
Description: According to the analyses shown in Figure 2, hsa-miR-140-5p Luminal A hsa-miR-374a 4 hsa-miR-335 hsa-miR-20b hsa-miR-20a hsa-miR-10b Her2 OE hsa-miR-374a hsa-miR-335 hsa-miR-20b hsa-miR-20a hsa-miR-10b Luminal B Ki67+ hsa-miR-143-3p hsa-miR-135a-5p 6 hsa-miR-3653 hsa-miR-3180/hsa-miR-3180-3p hsa-miR-30b-5p hsa-miR-374b-5p Luminal B Her2+ hsa-miR-135a-5p hsa-miR-143-3p hsa-miR-3180/ hsa-miR-3653 hsa-miR-3180-3p
hsa-miR-30b-5p hsa-miR-374b-5p Luminal B Ki67+ hsa-miR-24-3p 2 hsa-miR-542-3p TNBC (Basal Like) hsa-miR-24-3p hsa-miR-542-3p Luminal B Her2+ hsa-miR-190b hsa-miR-483-5p 2 TNBC (Basal Like) hsa-miR-190b hsa-miR-483-5p Luminal B Ki67+ hsa-miR-30e-5p hsa-miR-30c-1-3p 2 Luminal B Her2+ hsa-miR-30c-1-3p hsa-miR-30e-5p TNBC (Basal Like) hsa-miR-30e-5p hsa-miR-30c-1-3p Luminal B Ki67+ hsa-miR-32-5p 6 vs hsa-miR-26b-5p Luminal B Her2+ hsa-miR-30a-5p hsa-miR-100-5p hsa-miR-335-5p hsa-miR-497-5p Luminal B Ki67+ hsa-miR-3607-3p 1 vs Her2 OE Luminal B Ki67+ hsa-miR-93-5p 10 vs hsa-miR-15a-5p TNBC (Basal Like) hsa-miR-29c-3p hsa-miR-148a-3p hsa-let-7a-5p hsa-miR-142-5p hsa-miR-140-3p hsa-miR-195-5p hsa-miR-374a-5p hsa-miR-26a-5p Luminal B Her2+ hsa-miR-3614-3p hsa-miR-451a 2 vs TNBC (Basal Like) Luminal B Ki67+ hsa-miR-126-3p 1 vs Luminal B Her2+ vs TNBC (Basal Like) Description: According to the comparison of miRNAs shown in Table 2 , we find 1 kind of microRNA differentially distributed between Luminal A and Luminal B Her2+ tumors, 5 kinds between Luminal A and Her2 overexpression tumors, 6 kinds between Luminal B Ki67+ and Luminal B Her2+ tumors, 2 kinds between Luminal B Ki67+ and TNBC tumors, 2 kinds between Luminal B Her2+ and TNBC tumors, and 2 kinds between Luminal B Ki67+, Luminal B Her2+, and TNBC tumors. We also find that 6 of the same types of microRNAs were distributed in both Luminal B Ki67+ and Luminal B Her2+ tumors, 1 kind in both Luminal B Ki67+ and Her2 OE tumors, 10 kinds in both Luminal B Ki67+ and TNBC tumors, 2 kinds in both Luminal B Her2+ and TNBC tumors, and one kind in Luminal B Ki67+, Luminal B Her2+, and TNBC tumors Ki67+, Luminal B Her2+, and TNBC subtypes (Table 3) . Twenty kinds of miRNAs were homogenously distributed in tumors from different clinicopathological subtypes that included: 6 kinds of miRNAs between Luminal B Ki67+ and Luminal B Her2+ subtypes, 1 kind between Luminal B Ki67+ and Her2 overexpression subtypes, 10 kinds between Luminal B Ki67+ and TNBC subtypes, 2 kinds between Luminal B Her2+ and TNBC subtypes, and 1 kind between Luminal B Ki67+, Luminal B Her2+, and TNBC subtypes (Table 3) . A total of 37 miRNAs were significantly distributed in tumors between all clinicopathological subtypes ( Figure 3 ).
Discussion
Oncologists engage in discussion on cancer heterogeneity between individuals with more enthusiasm than they do when discussing the heterogeneity of the cancer itself, even though it has long been known that solid cancer is a heterogenous tissue with differential oxygen pressure, histological grade, and mRNA expression (Wilson et al., 1992; Aihara et al., 1994; Kitadai et al., 1995) . In addition, it has become gradually accepted that applying competition colonization tradeoff models to tumor growth and invasion dynamics can be useful for exploring the hypothesis that varying selection forces will result in predictable phenotypic differences in cells at the tumor invasive front compared to those in the core (Orlando et al., 2013) .
As shown in Table 1 , the diameter of a breast tumor must be more than or equal to 2 cm for the center and edge to be easily distinguished, according to Figure 1A . A recent study suggested that some key miRNAs may play signaling or regulatory roles in cancer progression (Hughes, 2009 ). On the other hand, the 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach for classifying patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum, which can be classified by immunohistochemical staining (Goldhirsch et al., 2011) . Therefore, we performed miRNA Arrays on the center and edges of tumors from different clinicopathological subtypes. Eleven types of expression profiles were obtained ( Figure 1A ), which included 5 center samples and 5 edge samples from 5 subtypes and 1 normal tissue ( Figure 1B) . Because all neoplastic parenchyma cells share at least one primary chromosomal abnormality, with subsequent clonal evolution along the lines of Darwinian selection occurring among various subclones carrying secondary aberrations (Teixeira et al, 2011) . We analyzed data under the hypothesis of tumorigenesis. First, abnormal orders of miRNA expression were removed that included edge<normal<center and center<normal<edge. Second, we obtained 4 orders of miRNA expression in each clinicopathological subtype, which included center>edge>normal, edge>center>normal, edge<center<normal, and center<edge<normal ( Figure 2) . Therefore, 8 kinds of miRNAs were differentially distributed in Luminal A, 84 kinds in Luminal B Ki67+, 52 kinds in Luminal B Her2+, 13 kinds in Her2 overexpression, and 50 kinds in TNBC subtypes (Table 2) . Furthermore, by comparative analyses, we found that 17 miRNAs were heterogeneously distributed in different clinicopathological subtypes, and 20 miRNAs were homogeneously distributed (Tables 3, Figure 3 ). With imaging times of less than 3 minutes by electron paramagnetic resonance imaging, it was possible to monitor the dynamics of oxygen changes in the tumors, and to chronically distinguish hypoxic regions from acutely hypoxic regions (Krishna et al., 2012) . We speculated that these differentially expressed miRNAs were probably related to degree of hypoxia, or even with angiogenesis. Therefore, we performed predictive analyses on miR-374a, -335, -20b, -20a, and -10b using bioinformatic tools (www.microrna.org), and found that miR-20a and miR-20b likely regulate target proteins, including vascular endothelial growth factor-A (VEGF-A) and hypoxia-inducible factor-1 (HIF-1), at the translational level. This regulatory mechanism was proven preliminarily with clinical experiments and subsequently published by Li et al (2012) .
Tumorigenesis and progression can be seen as evolutionary processes, in which the transformation of a normal cell into a tumor cell involves a number of limiting genetic and epigenetic events that occur in a series of discrete stages (Stransky et al, 2012) . Both functional and observational data implicate alterations in histone modifications, DNA promoter methylation, and non-coding RNA expression in carcinogenesis (Choudhry et al, 2011) . On the other hand, due to the wide range of biological functions of miRNAs, analyzing changes in overall miRNA expression levels within human tumors has helped identify miRNA signatures associated with diagnosis, staging, progression, prognosis, and response to treatment (Cortés-Sempere et al, 2011) . Thus, the miRNA Array screening of tumors from their centers and edges might provide a new method for studying cancer heterogeneity.
